阿里影業及貓眼娛樂續升6.5%-9% 內地暑假檔期電影票房破70億人幣
內地今年暑假檔期電影票房突破70億人民幣。相關股阿里影業(01060.HK)及貓眼娛樂(01896.HK)分別三連漲及四連漲,前者股價創兩個月高,最高見0.495元(暫受制250天線0.51元),現報0.49元,續升6.5%,成交增至1.57億股;後者股價突破百天線(8.21元),最高見8.67元,創逾兩個月高,現報8.49元,續升9%,成交增至770萬股,涉資6,441萬元。
據貓眼專業版日前數據顯示,截至7月10日11時16分,內地2023年暑假檔總票房(含預售)破70億元人民幣,其中阿里影業參與投資和發行的《消失的她》居榜首,檔期票房近31億元人民幣,票房佔比44.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.